GENEVA--(BUSINESS WIRE)--Sep 13, 2018--Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that several of its scientific and business leaders will be participating at upcoming industry conferences and events, as follows:
BioJapan 2018 10 – 12 October 2018, Pacifico Yokohama, Yokohama, Japan Selexis team members will attend and participate in business development and partnering activities. For more information, please visit: https://www.ics-expo.jp/biojapan/en/
BIO-Europe 24 th Annual International Partnering Conference 5 – 7 November 2018, Bella Center Copenhagen, Copenhagen, Denmark Selexis team members will attend and participate in business development and partnering activities. For more information, please visit: https://ebdgroup.knect365.com/bioeurope/
JAACT 2018 5 – 8 November 2018, Tsukuba International Congress Center, Tsukuba, Japan Selexis Chief Executive Officer Igor Fisch, PhD, will present, “Selexis Cell Line Development Platform, and Technologies for Assessment of Cell Line Integrity and Clonality,” followed by a joint Selexis/KBI presentation titled, “GENE to GMP in 9 Months – Accelerating the Development of Innovative Discoveries into Life-Changing Biological Medicines.” Additionally, Selexis will have representation at the JSR booth in the exhibit hall. For more information, please visit: https://www.aeplan.co.jp/jaact2018/index.html
10 th Annual PEGS Europe Protein & Antibody Engineering Summit 12 – 16 November 2018, Lisbon Congress Center, Lisbon, Portugal Selexis Chief Executive Officer Igor Fisch, PhD, will present “Selexis’ SUREs can and SURE signature: Technologies for Assessment of Cell Line Integrity and Clonality” on Wednesday, 14 November at 10:05 a.m. WET. Additionally, Selexis is a conference sponsor and exhibitor (booth #310). For more information, please visit: http://www.pegsummiteurope.com/
Antibody Engineering & Therapeutics 9 – 13 December 2018, Manchester Grand Hyatt San Diego, San Diego, CA Selexis team members will attend the conference. For more information, please visit: https://lifesciences.knect365.com/antibody-engineering-therapeutics/
About Selexis SA
Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical development and the manufacture of three commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SURE technology Platform™ to offer an end-to-end solution to industry. More information is available at www.selexis.com.
FOR MORE INFORMATION
View source version on businesswire.com:https://www.businesswire.com/news/home/20180913005087/en/
CONTACT: Media Inquiries for Selexis
Sam Brown Inc.
Mike Beyer, +1 312-961-2502
Company Inquiries for Selexis
Robert Meister, +1 602-953-1716
Head, Corporate Communications
KEYWORD: UNITED STATES EUROPE ASIA PACIFIC NORTH AMERICA CALIFORNIA DENMARK PORTUGAL SWITZERLAND JAPAN
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS INFECTIOUS DISEASES PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH
SOURCE: Selexis SA
Copyright Business Wire 2018.
PUB: 09/13/2018 08:00 AM/DISC: 09/13/2018 08:01 AM